Comparison · NCT00807989-4ebcee35
Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 52 Weeks at Initial Target Dose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 52 Weeks at Initial Target Dose. Trial comparisons, record NCT00807989-4ebcee35. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00807989-4ebcee35
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.478 | 0.378 | 0.58 | wilson | |
| Risk in group 2 | 0.641 | 0.53 | 0.739 | wilson | |
| Risk difference, group 1 minus group 2 | -0.163 | -0.303 | -0.0127 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.745 | 0.568 | 0.979 | log | |
| Odds ratio, group 1 over group 2 | 0.512 | 0.275 | 0.953 | log | |
| Number needed to treat, for one fewer participant with the outcome on Carbamazepine than on Lamotrigine/Valproate | 6.13 | 3.3 | 78.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Carbamazepine | Carbamazepine~Carbamazepine | 43 | 90 | OG000 |
| Group 2 | Lamotrigine/Valproate | Lamotrigine and Valproate combination therapy~Lamotrigine/Valproate | 50 | 78 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Seizure Free Rate for 52 Weeks at Initial Target Dose
- Description
- Time frame
- 52 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
- NCT number
- NCT00807989
- Phases
- PHASE4
- Conditions
- Epilepsy
- Interventions
- Carbamazepine, Lamotrigine/Valproate
- Lead sponsor
- Yonsei University
- Results first posted
- 2015-05-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00807989?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00807989-4ebcee35